DARPA's Biological Technologies Office Just Pre-Released Four FY26 SBIR Topics — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Why the Direct-to-Phase-II Slots Are the Real Story.

On April 30, 2026, DARPA's Biological Technologies Office (BTO) pre-released four new SBIR/STTR topics under the FY26 Broad Agency Announcement. The pre-release window opens for full proposals on May 6 and closes June 3, 2026 — a remarkably tight five-week window for topics that span surgical implants, autonomous medical robotics, battlefield blood transfusion, and one-shot canine drug regimens. The four topics together cover a spectrum of biotech defense priorities that have been building inside BTO over the past two years and are now consolidating into specific small-business solicitations.

Three details make this round different from a standard DoD SBIR cycle. First, two of the four topics are Direct-to-Phase-II (DP2) opportunities up to $1.5M each, which bypass the $300K Phase I feasibility gate that normally consumes the first 6–12 months of a program. Second, the award sizes are larger than typical DoD SBIR: $300K Phase I, $1.5M–$1.8M Phase II, with one topic combining $300K Phase I plus $1.5M DP2 plus $1.8M follow-on Phase II — a stacked sequence not common in other agencies' SBIR portfolios. Third, the topic mix tells you exactly where BTO sees the frontier: real-time decision support for medics, biological-electronic interfaces, autonomous surgical and rescue robotics, and translational veterinary medicine as a pathway to human applications.

Tracking DoD SBIR/STTR opportunities? See our DARPA Grants Hub for active BAAs, topic releases, and Phase II conversion rates.

The Four Topics, In Order of Strategic Significance

Smart Whole Blood Field Transfusion System (SWiFT)

SWiFT addresses one of the longest-standing problems in combat casualty care: how to keep whole blood viable and deliverable in austere environments where refrigeration, power, and trained medics are unreliable. The award stack here is the most aggressive in the round — $300K Phase I, $1.5M Direct-to-Phase-II, and $1.8M Phase II — signaling that BTO expects strong DP2 applicants from teams that already have functional prototypes from prior DoD CCC, USAMRDC, or commercial blood-banking work.

The technical envelope is wide: real-time blood quality monitoring, contamination detection, temperature stabilization without active refrigeration, automated transfusion dosing, and integration with the existing Tactical Combat Casualty Care (TCCC) workflow. Applicants with a credible "smart" sensor stack — biosensors for hemolysis, pH, coagulation status — paired with miniaturized fluid-handling hardware will be the natural fit. Teams without prior blood-handling regulatory exposure (FDA, AABB) will need to either bring that expertise in through a subcontractor or honestly scope a Phase I limited to component-level demonstration.

The DP2 path is the right consideration for any team with prior SBIR Phase I work on transfusion adjuncts, miniaturized blood-monitoring sensors, or field-portable fluid management. The standard Phase I path is the right consideration for teams whose IP and prototype maturity sit at TRL 3–4 and need a structured feasibility year before scaling.

Extremity Platform for On-Demand Surgical Implantation and Tissue Integration with Osteochondral Neogenesis (EXPOSITION)

EXPOSITION is a Direct-to-Phase-II only topic at $1.5M, which is a strong signal that DARPA already knows the small ecosystem of teams that could credibly compete. The target is on-demand, field-deployable surgical implants that integrate with bone and cartilage — addressing extremity injuries that currently require evacuation to a Role 3 or higher facility for limb-salvage surgery.

The technical problem combines bioactive scaffolds, on-demand fabrication (likely 3D printing or modular component assembly), and osteochondral regeneration — meaning the implant must support both bone and joint cartilage growth at the interface. The materials science alone — bioactive polymers, calcium phosphate composites, growth-factor delivery — is its own technical mountain, before adding the field-deployment constraints.

Teams to watch: regenerative medicine startups with FDA 510(k) experience on orthopedic devices, university spinouts with strong osteochondral animal data, and surgical-robotics companies that have started to integrate biological materials. The DP2-only structure means BTO is not interested in feasibility-stage proposals here — it wants teams that can credibly demonstrate a working implant in a Phase II window.

Medical Swarm Robotics for Extraction and Life-Saving Interventions

This topic — $300K Phase I, $1.5M Phase II — is the most ambitious from a robotics-and-autonomy standpoint. The vision is coordinated robotic systems that can locate casualties in contested or contaminated environments, perform initial triage and stabilization, and either deliver casualties to evacuation points or stabilize them in place until evacuation is possible. The "swarm" framing implies multiple cooperating units rather than a single robot — a deliberate echo of broader DoD autonomy work in unmanned aerial and ground systems.

This is a topic where the right team probably already exists: a robotics company with prior DARPA RACER, OFFSET, or CRASH program experience, paired with a medical-technology subcontractor with TCCC expertise. Single-discipline applicants (pure robotics or pure medical devices) will struggle to score well; multidisciplinary teams with a credible integration story will dominate.

The Phase I path is the right consideration here for teams that need to demonstrate the coordination protocols and casualty-detection sensing in a constrained scenario. The full Phase II envelope is appropriate for the field-deployment demonstration in year two.

Broadening Availability of Regimens for K-9s (BARK)

BARK is a smaller-budget topic — $150K Phase I, $1.3M Phase II — but it is more strategically interesting than the budget suggests. The stated goal is broadening drug regimens available for military working dogs, but the underlying logic is dual-use: veterinary applications are often a translational stepping stone to human medicine, and one-shot or long-acting drug formulations developed for working dogs can be adapted for soldier readiness, civilian veterinary markets, and downstream human medicine.

This is the right topic for small pharmaceutical companies, drug-delivery startups, and veterinary biotech firms that have struggled to find non-dilutive capital. Working dogs are an underserved market for advanced therapeutics, and DARPA is essentially using BARK to seed the pipeline. Teams with prior NIH SBIR experience in long-acting formulations, depot drug delivery, or veterinary biologics are the natural fit.

Why the Direct-to-Phase-II Structure Matters

In a normal SBIR cycle, a Phase I award funds 6–12 months of feasibility work at roughly $250K–$300K, and only Phase I winners can apply for Phase II. That structure protects the agency from over-investing in unproven concepts, but it imposes a 12–18-month delay on technology that is already mature.

Direct-to-Phase-II awards solve that delay for teams that have done their feasibility work outside SBIR — typically through prior university research, internal R&D, other agency funding, or a previous SBIR Phase I from a different topic. DP2 lets DARPA buy the next 24 months of development directly, accelerating mature technology toward demonstration without re-litigating feasibility.

For applicants, the strategic question is whether their prior work documents Phase-I-equivalent feasibility. DARPA will require explicit evidence — prototype data, third-party validation, prior funding history — that establishes the team has cleared the feasibility bar that a standard Phase I would otherwise impose. The most common DP2 application failure is asserting feasibility without documenting it.

A second consideration: DP2 awards do not stack neatly with normal Phase II, so applicants pursuing the SWiFT topic must decide between the DP2 path and the Phase I → Phase II path. The stacked $300K + $1.5M + $1.8M envelope on SWiFT is structured to allow a sequence (Phase I, then DP2, then Phase II) for teams that win Phase I and exceed expectations — but applicants typically apply for one path at a time.

The Five-Week Calendar Through June 3

For teams considering one or more of these topics, the working calendar runs roughly like this:

Days one through five — topic match and team formation. Read the full topic descriptions on the DARPA SBIR/STTR portal and DSIP. Identify the right principal investigator and confirm any subcontractor or university partner relationships. For DP2 topics, audit prior work for feasibility documentation.

Days five through fifteen — technical approach. Draft the technical objectives, key milestones, deliverables, and risk-mitigation strategies. Confirm any data, IP, or facility dependencies. Begin assembling the team's prior performance evidence.

Days fifteen through thirty — budget and commercial path. Build the cost volume by task and labor category. Draft the commercialization plan — DARPA scores this seriously, particularly for medical topics where the commercial path is often more credible than for pure-defense topics. Confirm letters of support from clinical partners, hospitals, veterinary networks, or transition customers.

Final week — internal review, DSIP submission, format checks, and final submission with at least 72 hours of buffer. DSIP has well-documented submission quirks that punish late submitters.

The Broader Signal From BTO

The four topics together tell a story about where BTO is investing FY26 attention. Battlefield medicine continues to be the dominant theme — SWiFT and Medical Swarm Robotics both directly support the prolonged-field-care doctrine that has shaped DoD medical R&D since 2015. EXPOSITION extends that theme into the surgical recovery phase: keep the casualty alive in the field, then begin definitive repair before evacuation. BARK uses the working-dog domain as a translational platform that benefits military readiness, veterinary medicine, and downstream human applications.

For small businesses in biotech, medical devices, and robotics, this round is also a useful litmus test of how DoD SBIR is operating after the April 2026 SBIR/STTR reauthorization (S. 3971) that extended the program through 2031. The DP2 structures, larger award sizes, and topic specificity in BTO's FY26 release suggest that DARPA is moving faster and committing more per topic than in prior cycles — a pattern other defense agencies are likely to follow as their FY26 BAAs roll out across May and June.

Teams that have been holding mature prototypes waiting for the right SBIR window have one. The window closes June 3.